Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Hypertension
Intervention: Azilsartan medoxomil and chlorthalidone (Drug); Azilsartan medoxomil and hydrochlorothiazide (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Takeda Official(s) and/or principal investigator(s): Executive Medical Director, Study Director, Affiliation: Takeda
Summary
The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs
hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in
participants with moderate to severe essential hypertension.
Clinical Details
Official title: A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure
Secondary outcome: Change From Baseline in Trough, Sitting, Clinic Diastolic Blood PressureChange From Baseline in Mean Trough Systolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring. Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring. Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic Blood Pressure Targets, Defined as <140 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <130 mm Hg for Participants With Diabetes or Chronic Kidney Disease Percentage of Participants Who Reached Their Trough, Sitting, Clinic Diastolic Blood Pressure Target, Defined as <90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <80 mm Hg for Participants With Diabetes or Chronic Kidney Disease. Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic and Diastolic Blood Pressure Targets, Defined as <140/90 mm Hg Without Diabetes or Chronic Kidney Disease or <130/80 mm Hg With Diabetes or Chronic Kidney Disease
Detailed description:
According to the World Health Organization, hypertension is the most common attributable
cause of preventable death in developed nations, as uncontrolled hypertension greatly
increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure.
Despite the availability of antihypertensive agents, hypertension remains inadequately
controlled; only about one-third of patients continue to maintain control successfully.
Although most antihypertensive agents are effective at the appropriate dose, the majority
have side effects that limit their use. As a class, angiotensin II receptor blockers
generally are considered more tolerable than other classes of antihypertensive agents.
TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker being evaluated by
Takeda to treat essential hypertension.
Treatments for essential hypertension commonly include use of a thiazide-like diuretic,
either alone or as part of combination treatment. Although chlorthalidone was commonly
prescribed in the past, its use has widely been replaced with hydrochlorothiazide,
presumably due to a lack of available combination products containing chlorthalidone, the
assumption that hydrochlorothiazide and chlorthalidone have similar antihypertensive effects
and cardiovascular benefits, and the perception that chlorthalidone use is associated with a
greater frequency of hypokalemia. However, the frequency of hypokalemia with chlorthalidone
use is relatively low in the dose range of 12. 5 to 25 mg and these doses have been shown to
be associated with potent blood pressure reduction. Several long-term outcomes trials have
shown that blood pressure reductions associated with chlorthalidone treatment reduce risk of
cardiovascular morbidity and mortality.
Most hypertensive patients require two or more agents to achieve target blood pressure and
diuretics are commonly used in combination with other antihypertensive agents. This trial is
designed to compare chlorthalidone and hydrochlorothiazide when coadministered with
azilsartan medoxomil.
Participants in this study will receive either chlorthalidone or hydrochlorothiazide in
combination with azilsartan medoxomil. Total commitment time for this study is about 13
weeks. Participants will be required to wear a blood pressure monitor for three 24 hours
periods during the study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic
SBP greater than or equal to 160 and less than or equal to 190 mm Hg on Day - 1; or
the participant has not received antihypertensive treatment within 28 days prior to
Screening and has a mean sitting clinic SBP greater than or equal to 160 and less
than or equal to 190 mm Hg at the Screening Visit and on Day - 1.
2. Females of childbearing potential who are sexually active agree to routinely use
adequate contraception from Screening through 30 days after the last administered
study drug dose.
3. Has clinical laboratory test results (clinical chemistry, hematology, and complete
urinalysis) within the reference range for the testing laboratory or the investigator
does not consider the results to be clinically significant.
4. Is willing to discontinue current antihypertensive medications on Day - 21 or Day -28
if the participant is on amlodipine or chlorthalidone.
Exclusion Criteria:
1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg on Day - 1.
2. Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficient
quality.
3. Works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]).
4. Has an upper arm circumference less than 24 cm or greater than 42 cm.
5. Is noncompliant (less than 70% or greater than 130%) with study medication during the
placebo run-in period.
6. Has secondary hypertension of any etiology (eg, renovascular disease,
pheochromocytoma, Cushing's syndrome).
7. Has a recent history (within the last 6 months) of myocardial infarction, heart
failure, unstable angina, coronary artery bypass graft, percutaneous coronary
intervention, hypertensive encephalopathy, cerebrovascular accident, or transient
ischemic attack.
8. Has clinically significant cardiac conduction defects (ie, third-degree
atrioventricular block, sick sinus syndrome, atrial fibrillation, or atrial flutter).
9. Has hemodynamically significant left ventricular outflow obstruction due to aortic
valvular disease.
10. Has severe renal dysfunction or disease [based on estimated glomerular filtration
rate less than 30 mL/min/1. 73m2 at Screening].
11. Has known or suspected unilateral or bilateral renal artery stenosis.
12. Has a history of cancer that has not been in remission for at least 5 years prior to
the first dose of study drug. (This criterion does not apply to those participants
with basal cell or stage I squamous cell carcinoma of the skin).
13. Has poorly-controlled type 1 or type 2 diabetes mellitus at Screening.
14. Has hypokalemia or hyperkalemia (defined as serum potassium outside of the normal
reference range of the central laboratory).
15. Has an alanine aminotransferase or aspartate aminotransferase level of greater than
2. 5 times the upper limit of normal, active liver disease, or jaundice.
16. Has any other known serious disease or condition that would compromise safety, might
affect life expectancy, or make it difficult to successfully manage and follow the
participant according to the protocol.
17. Has known hypersensitivity to angiotensin II receptor blockers or thiazide-type
diuretics or other sulfonamide-derived compounds.
18. Has been randomized in a previous azilsartan medoxomil study.
19. Currently participating in another investigational study or is receiving or has
received any investigational compound within 30 days prior to Screening.
20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
Locations and Contacts
Moscow, Russian Federation
Perm, Russian Federation
St. Petersburg, Russian Federation
Birmingham, Alabama, United States
Gulf Shores, Alabama, United States
Scottsboro, Alabama, United States
Gilbert, Arizona, United States
Sierra Vista, Arizona, United States
Paramount, California, United States
Sacramento, California, United States
San Diego, California, United States
Colorado Springs, Colorado, United States
Wheat Ridge, Colorado, United States
Milford, Connecticut, United States
Adventura, Florida, United States
Aventura, Florida, United States
Brooksville, Florida, United States
Crystal River, Florida, United States
DeLand, Florida, United States
Doral, Florida, United States
Miami, Florida, United States
Naranja, Florida, United States
Sarasota, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Winter Haven, Florida, United States
Atlanta, Georgia, United States
Stockbridge, Georgia, United States
Suwanee, Georgia, United States
Huntsville, Illinois, United States
Bloomington, Indiana, United States
Valparaiso, Indiana, United States
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
West Yarmouth, Massachusetts, United States
Ann Arbor, Michigan, United States
St. Louis, Missouri, United States
St. Peters, Missouri, United States
New Windsor, New York, United States
Asheboro, North Carolina, United States
Cincinnati, Ohio, United States
Kettering, Ohio, United States
Downingtown, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Lansdale, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Goose Creek, South Carolina, United States
Taylors, South Carolina, United States
Bryan, Texas, United States
San Antonio, Texas, United States
Ettrick, Virginia, United States
Seattle, Washington, United States
Madison, Wisconsin, United States
Additional Information
EDARBYCLOR Package Insert FDA Safety Alerts and Recalls
Starting date: February 2009
Last updated: January 4, 2012
|